Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis

Objective: To synthesize the best evidence surrounding the efficacy of cannabinoids for acute pain in the clinical setting based on subjective pain scores and observed adverse effects.Design: Systematic review with meta-analysis.Data Sources: PubMed, ...

View original

1. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162–171 [PubMed] [Google Scholar]

2. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735–744 [PMC free article] [PubMed] [Google Scholar]

3. Whiting PF, Wolff RF, Deshpande S, et al.. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456–2473 [PubMed] [Google Scholar]

4. Madden K, van der Hoek N, Chona S, et al.. Cannabinoids in the management of musculoskeletal pain: a critical review of the evidence. JBJS Rev. 2018;6:e7 [PubMed] [Google Scholar]

5. Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2:160–166 [PMC free article] [PubMed] [Google Scholar]

6. Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E796 [PubMed] [Google Scholar]

7. Stevens A, Higgins M. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. Acta Anaesthesiol Scand. 2017;61:268–280 [PubMed] [Google Scholar]

8. Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. [PMC free article] [PubMed] [Google Scholar]

9. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons: Chichester, UK, 2008 [Google Scholar]

10. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013;38:1984. [PMC free article] [PubMed] [Google Scholar]

11. Kalliomäki J, Philipp A, Baxendale J, et al.. Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2012;39:336–342 [PubMed] [Google Scholar]

12. Kraft B, Frickey NA, Kaufmann RM, et al.. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101–110 [PubMed] [Google Scholar]

13. Lee MC, Ploner M, Wiech K, et al.. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013;154:124–134 [PMC free article] [PubMed] [Google Scholar]

14. Redmond WJ, Goffaux P, Potvin S, et al.. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin. 2008;24:1017–1024 [PubMed] [Google Scholar]

15. Rukwied R, Watkinson A, McGlone F, et al.. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain. 2003;102:283–288 [PubMed] [Google Scholar]

[PubMed] [Google Scholar]

16. Cooper ZD, Bedi G, Ramesh D, et al.. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43:2046–2055 [PMC free article] [PubMed] [Google Scholar]

17. Cooper ZD, Haney M. Sex-dependent effects of cannabis-induced analgesia. Drug Alcohol Depend. 2016;167:112–120 [PMC free article] [PubMed] [Google Scholar]

18. Esfandyari T, Camilleri M, Busciglio I, et al.. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol. 2007;293:G137–G145 [PubMed] [Google Scholar]

19. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59:261–275 [PubMed] [Google Scholar]

20. Naef M, Curatolo M, Petersen-Felix S, et al.. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105:79–88 [PubMed] [Google Scholar]

21. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-

tetrahydrocannabinol and morphine. Eur J Pharmacol. 2006;530:54–58 [PubMed] [Google Scholar]

22. van Amerongen G, Siebenga P, de Kam ML, et al.. Effect profile of paracetamol, Δ9-THC and promethazine using an evoked pain test battery in healthy subjects. Eur J Pain. 2018;22:1331–1342 [PubMed] [Google Scholar]

23. Wallace M, Schulteis G, Atkinson JH, et al.. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007;107:785–796 [PubMed] [Google Scholar]

24. Walter C, Oertel BG, Felden L, et al.. Brain mapping-based model of Δ(9)-tetrahydrocannabinol effects on connectivity in the pain matrix. Neuropsychopharmacology. 2016;41:1659–1669 [PMC free article] [PubMed] [Google Scholar]

25. De Vita MJ, Moskal D, Maisto SA, et al.. Association of cannabinoid administration with experimental pain in healthy adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75:1118–1127 [PMC free article] [PubMed] [Google Scholar]

26. Ouzzani M, Hammady H, Fedorowicz Z, et al.. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. [PMC free article] [PubMed] [Google Scholar]

27. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. John Wiley & Sons: Chichester, UK, 2011 [Google Scholar]

28. Welch VA, Akl EA, Guyatt G, et al.. GRADE equity guidelines: 1. Considering health equity in GRADE guideline development: introduction and rationale. J Clin Epidemiol. 2017;90:59–67 [PMC free article] [PubMed] [Google Scholar]

29. Balshem H, Helfand M, Schünemann HJ, et al.. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406 [PubMed] [Google Scholar]

30. Higgins JPT, Thompson SG, Deeks JJ, et al.. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560 [PMC free article] [PubMed] [Google Scholar]

31. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558 [PubMed] [Google Scholar]

32. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53:769–775 [PubMed] [Google Scholar]

33. Buggy DJ, Toogood L, Maric S, et al.. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol

in postoperative pain. Pain. 2003;106:169–172 [PubMed] [Google Scholar]

34. Jain AK, Ryan JR, McMahon FG, et al.. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21:320S–326S [PubMed] [Google Scholar]

35. Kalliomaki J, Segerdahl M, Webster L, et al.. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scand J Pain. 2013;4:17–22 [PubMed] [Google Scholar]

36. Levin DN, Dulberg Z, Chan A, et al.. A randomized controlled trial of nabilone for the prevention of postoperative nausea and vomiting in elective surgery. Can J Anaesth. 2017;64:385–395 [PubMed] [Google Scholar]

37. Ostenfeld T, Price J, Albanese M, et al.. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain. 2011;27:668–676 [PubMed] [Google Scholar]

38. Bruni N, Della Pepa C, Oliaro-Bosso S, et al.. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018;23:2478 [Google Scholar]

[Google Scholar]

39. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360 [PubMed] [Google Scholar]

40. Hartman RL, Brown TL, Milavetz G, et al.. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem. 2015;61:850–869 [PubMed] [Google Scholar]

42. Hickernell TR, Lakra A, Berg A, et al.. Should cannabinoids be added to multimodal pain regimens after total hip and knee arthroplasty? J Arthroplasty. 2018;33:3637–3641 [PubMed] [Google Scholar]

43. Holdcroft A, Maze M, Dore C, et al.. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040–1046 [PubMed] [Google Scholar]

44. Prabhu AJ. Weeding out the problem: the impact of preoperative cannabinoid use on pain in the perioperative period. Pain. 2018;16:17 [PubMed] [Google Scholar]

45. Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 2017;173:144–150 [PMC free article] [PubMed] [Google Scholar]

46. Donvito G, Nass SR, Wilkerson JL, et al.. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43:52. [PMC free article] [PubMed] [Google Scholar]

47. Nagarkatti P, Pandey R, Rieder SA, et al.. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333–1349 [PMC free article] [PubMed] [Google Scholar]

48. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB 2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009;11:1–31 [PMC free article] [PubMed] [Google Scholar]

49. Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem. 2001;81:715–723 [PubMed] [Google Scholar]

50. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400. [PubMed] [Google Scholar]

51. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8:403–421 [PMC free article] [PubMed] [Google Scholar]

52. Urits I, Borchart M, Hasegawa M, et al.. An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther. 2019;8:41–51 [PMC free article] [PubMed] [Google Scholar]

53. Ward SJ, McAllister SD, Kawamura R, et al.. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2014;171:636–645 [PMC free article] [PubMed] [Google Scholar]

54. Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, et al.. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Mol Brain. 2018;11:51. [PMC free article] [PubMed] [Google Scholar]

55. Li H, Kong W, Chambers CR, et al.. The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cell Immunol. 2018;329:1–9 [PMC free article] [PubMed] [Google Scholar]

56. Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, et al.. Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf. 2011;6:237–249 [PubMed] [Google Scholar]

57. Hammell D, Zhang L, Ma F, et al.. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20:936–948 [PMC free article] [PubMed] [Google Scholar]

58. Philpott HT, O'Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158:2442. [PMC free article] [PubMed] [Google Scholar]